Avidity Biosciences Inc [RNA] stock prices are up 4.02% to $35.95 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RNA shares have gain 7.22% over the last week, with a monthly amount glided 23.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Bernstein started tracking the stock with Outperform rating on June 24, 2025, and set its price target to $50. On June 17, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $55 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $65 on June 11, 2025. Citigroup initiated its recommendation with a Buy and recommended $70 as its price target on March 13, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on March 12, 2025, and assigned it a price target of $72. In a note dated March 07, 2025, Scotiabank initiated an Sector Outperform rating and provided a target price of $70 on this stock.
The stock price of Avidity Biosciences Inc [RNA] has been fluctuating between $21.51 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $35.95 at the most recent close of the market. An investor can expect a potential return of 94.71% based on the average RNA price forecast.
Analyzing the RNA fundamentals
The Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 8.93M for trailing twelve months, representing a drop of -55.60%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.53%, Pretax Profit Margin comes in at -41.36%, and Net Profit Margin reading is -41.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.27 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.79 points at the first support level, and at 33.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.57, and for the 2nd resistance point, it is at 37.19.
Ratios To Look Out For
It’s worth pointing out that Avidity Biosciences Inc [NASDAQ:RNA]’s Current Ratio is 16.91. On the other hand, the Quick Ratio is 16.91, and the Cash Ratio is 3.0. Considering the valuation of this stock, the price to sales ratio is 485.26, the price to book ratio is 3.26.
Transactions by insiders
Recent insider trading involved Gallagher Kathleen P., Chief Program Officer, that happened on Jun 17 ’25 when 911.0 shares were sold. Officer, KATHLEEN GALLAGHER completed a deal on Jun 17 ’25 to buy 911.0 shares. Meanwhile, Chief Scientific Officer Flanagan W. Michael sold 20000.0 shares on Jun 11 ’25.
